(reported by the Company)
No items found
In the developed world respiratory distress remains the most common cause of death within the first year of a newborn's life. It is a condition that is widespread amongst the almost 15 million premature babies born each year and exists within nearly all babies born before 28 weeks of pregnancy. As a result, the vast majority of very premature infants will require some form of respiratory support to survive.
Currently, Continuous Positive Airway Pressure (CPAP) and High Flow Nasal Cannula (HFNC) are the gold standard methods for non-invasive respiratory support. However, due to various leaks which can occur at the nose, the mouth and the stomach, these systems can fail to accurately deliver a set pressure to the lungs. Getting the pressure setting wrong can have serious health consequences, results in slower physical development and leads to increased lengths of stay in the hospital.
Born in 2018, Ventora Medical is a Melbourne-based medical device company with a vision to address this clinical need. Our device will allow clinicians to provide proactive treatment tailored to the individual infant; improving health outcomes and reducing significant costs in corrective procedures and length of stay in the NICU.
Our team comprises passionate biomedical engineers, healthcare and business experts from a diverse range of backgrounds and we are passionate and committed to setting a new standard of neonatal care.
|Hardware & devices, Health & biotech
|ASX Listing Code (if applicable):
|Year of Commencement:
Melbourne, VIC 3000, AU